Please use this identifier to cite or link to this item: https://www.arca.fiocruz.br/handle/icict/51167

Type
Preprint
Copyright
Open access
Sustainable Development Goals
03 Saúde e Bem-Estar
Collections
Share

Statistics
Metadata
Show full item record

CHANGE IN COVID-19 RISK OVER TIME FOLLOWING VACCINATION WITH CORONAVAC: A TESTNEGATIVE CASE-CONTROL STUDY
Hitchings, Matt D. T. et al. | Date Issued: 2021
Author
Hitchings, Matt D. T.
Ranzani, Otavio T.
Lind, Margaret L.
Dorion, Murilo
D’Agostini, Tatiana Lang
Paula, Regiane Cardoso de
Paula, Olivia Ferreira Pereira de
Villela, Edlaine Faria de Moura
Torres, Mario Sergio Scaramuzzini
Oliveira, Silvano Barbosa de
Schulz, Wade
Almiron, Maria
Said, Rodrigo
Oliveira, Roberto Dias de
Silva, Patricia Vieira da
Araújo, Wildo Navegantes de
Gorinchteyn, Jean Carlo
Dean, Natalie E.
Andrews, Jason R.
Cummings, Derek A. T.
Ko, Albert I.
Croda, Julio
Affilliation
University of Florida. Department of Biostatistics. College of Public Health & Health Professions. Gainesville, FL, USA.
Barcelona Institute for Global Health. ISGlobal. Barcelona, Spain / Universidade de São Paulo. Faculdade de Medicina. Hospital das Clínicas HCFMUSP. Pulmonary Division, Heart Institute (InCor). São Paulo, SP, Brazil.
Yale School of Public Health. Department of Epidemiology of Microbial Diseases. New Haven, CT, USA.
Yale School of Public Health. Department of Epidemiology of Microbial Diseases. New Haven, CT, USA.
Disease Control Coordination of the São Paulo State Department of Health. São Paulo, SP, Brazil.
Disease Control Coordination of the São Paulo State Department of Health. São Paulo, SP, Brazil.
Disease Control Coordination of the São Paulo State Department of Health. São Paulo, SP, Brazil.
Disease Control Coordination of the São Paulo State Department of Health. São Paulo, SP, Brazil.
Municipal Health Secretary of Manaus. Manaus, AM, Brazil.
Pan American Health Organization. Brasília, DF, Brazil / Universidade de Brasília. Brasília, DF, Brazil.
Yale University School of Medicine. Department of Laboratory Medicine. New Haven, CT, USA.
Pan American Health Organization. Brasília, DF, Brazil.
Pan American Health Organization. Brasília, DF, Brazil.
State University of Mato Grosso do Sul. Dourados, MS, Brazil.
Universidade Federal de Mato Grosso do Sul. Campo Grande, MS, Brazil.
Pan American Health Organization. Brasília, DF, Brazil / Universidade de Brasília, Brasília, Distrito Federal, Brazil / National Institute for Science and Technology for Health Technology Assessment. Porto Alegre, RS, Brazil.
Health Secretariat of the State of São Paulo. São Paulo, SP, Brazil.
Emory University. Rollins School of Public Health. Department of Biostatistics & Bioinformatics. USA.
Stanford University, Stanford. Division of Infectious Diseases and Geographic Medicine. CA, USA.
University of Florida. Department of Biology. Gainesville, FL, USA / University of Florida. Emerging Pathogens Institute. Gainesville, FL, USA.
Yale School of Public Health. Department of Epidemiology of Microbial Diseases. New Haven, CT, USA / Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brazil.
Yale School of Public Health. Department of Epidemiology of Microbial Diseases. New Haven, CT, USA / Universidade Federal de Mato Grosso do Sul. Campo Grande, MS, Brazil / Fundação Oswaldo Cruz. Fiocruz Mato Grosso do Sul. Campo Grande, Mato Grosso do Sul, Brazil.
Abstract
Objective To estimate the change in odds of covid-19 over time following primary series completion of the inactivated whole virus vaccine, CoronaVac (Sinovac Biotech) in São Paulo state, Brazil. Design Test negative case-control study. Setting Community testing for covid-19 in São Paulo state, Brazil. Participants Adults aged 18-120 years who were residents of São Paulo state, without a previous laboratory-confirmed covid-19 infection, who received only two doses of CoronaVac, and underwent reverse transcription polymerase chain reaction (RT-PCR) testing for SARS-CoV-2 from 17 January to 30 September 2021. Main outcome measures RT-PCR-confirmed symptomatic covid-19 and associated hospital admissions and deaths. Cases were pair-matched to test-negative controls by age (in 5-year bands), municipality of residence, healthcare worker (HCW) status, and date of RT-PCR test (±3 days). Conditional logistic regression was adjusted for sex, number of covid-19-associated comorbidities, race, and previous acute respiratory infection. Results From 137,820 eligible individuals, 37,929 cases with symptomatic covid-19 and 25,756 testnegative controls with covid-19 symptoms were formed into 37,929 matched pairs. Adjusted odds ratios of symptomatic covid-19 increased with time since series completion, and this increase was greater in younger individuals, and among HCWs compared to non-HCWs. Adjusted odds ratios of covid-19 hospitalisation or death were significantly increased from 98 days since series completion, compared to individuals vaccinated 14-41 days previously: 1.40 (95% confidence interval 1.09 to 1.79) from 98-125 days, 1.55 (1.16 to 2.07) from 126-153 days, 1.56 (1.12 to 2.18) from 154-181 days, and 2.12 (1.39-3.22) from 182 days. Conclusions In the general population of São Paulo state, Brazil, an increase in odds of moderate and severe covid-19 outcomes was observed over time following primary series completion with CoronaVac.
Keywords in Portuguese
COVID-19
CoronaVac
Vacinas
Vacinas de Produtos Inativados
Estudos de Casos e Controles
Brasil
 
Keywords
COVID-19
CoronaVac
Vaccines
Vaccines, Inactivated
Case-Control Studies
Brazil
 
Publisher
MedRxiv
Citation
HITCHINGS, Matt D. T. et.al. Change in COVID-19 risk over time following vaccination with CoronaVac: a testnegative case-control study. MedRxiv preprint, p. 1-23, 2021.
DOI
10.1101/2021.12.23.21268335